Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Klotho Protects Dopaminergic Neuron Oxidant-Induced Degeneration by Modulating ASK1 and p38 MAPK Signaling Pathways.

Brobey RK, German D, Sonsalla PK, Gurnani P, Pastor J, Hsieh CC, Papaconstantinou J, Foster PP, Kuro-o M, Rosenblatt KP.

PLoS One. 2015 Oct 9;10(10):e0139914. doi: 10.1371/journal.pone.0139914. eCollection 2015.

2.

Engrailed-2 (En2) deletion produces multiple neurodevelopmental defects in monoamine systems, forebrain structures and neurogenesis and behavior.

Genestine M, Lin L, Durens M, Yan Y, Jiang Y, Prem S, Bailoor K, Kelly B, Sonsalla PK, Matteson PG, Silverman J, Crawley JN, Millonig JH, DiCicco-Bloom E.

Hum Mol Genet. 2015 Oct 15;24(20):5805-27. doi: 10.1093/hmg/ddv301. Epub 2015 Jul 28.

3.

The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism.

Sonsalla PK, Coleman C, Wong LY, Harris SL, Richardson JR, Gadad BS, Li W, German DC.

Exp Neurol. 2013 Dec;250:376-83. doi: 10.1016/j.expneurol.2013.10.014. Epub 2013 Oct 30.

4.

Coordinated role of voltage-gated sodium channels and the Na+/H+ exchanger in sustaining microglial activation during inflammation.

Hossain MM, Sonsalla PK, Richardson JR.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):355-64. doi: 10.1016/j.taap.2013.09.011. Epub 2013 Sep 24.

5.

Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.

Lee KW, Im JY, Woo JM, Grosso H, Kim YS, Cristovao AC, Sonsalla PK, Schuster DS, Jalbut MM, Fernandez JR, Voronkov M, Junn E, Braithwaite SP, Stock JB, Mouradian MM.

Neurotherapeutics. 2013 Jan;10(1):143-53. doi: 10.1007/s13311-012-0165-2.

6.

Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

Sonsalla PK, Wong LY, Harris SL, Richardson JR, Khobahy I, Li W, Gadad BS, German DC.

Exp Neurol. 2012 Apr;234(2):482-7. doi: 10.1016/j.expneurol.2012.01.022. Epub 2012 Jan 28.

7.

Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation.

Lee KW, Zhao X, Im JY, Grosso H, Jang WH, Chan TW, Sonsalla PK, German DC, Ichijo H, Junn E, Mouradian MM.

PLoS One. 2012;7(1):e29935. doi: 10.1371/journal.pone.0029935. Epub 2012 Jan 10.

8.

Parkinson's Disease: A Role for the Immune System.

German DC, Eagar T, Sonsalla PK.

Curr Mol Pharmacol. 2011 Jun 15. [Epub ahead of print]

PMID:
21675953
9.

Enhanced phosphatase activity attenuates ╬▒-synucleinopathy in a mouse model.

Lee KW, Chen W, Junn E, Im JY, Grosso H, Sonsalla PK, Feng X, Ray N, Fernandez JR, Chao Y, Masliah E, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM.

J Neurosci. 2011 May 11;31(19):6963-71. doi: 10.1523/JNEUROSCI.6513-10.2011.

10.

The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.

Sonsalla PK, Wong LY, Winnik B, Buckley B.

Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4.

11.

Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease.

Sonsalla PK, Zeevalk GD, German DC.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S116-8. doi: 10.1016/j.parkreldis.2008.04.008. Epub 2008 Jun 25. Review.

12.

Na(+)/H(+) exchanger inhibition modifies dopamine neurotransmission during normal and metabolic stress conditions.

Rocha MA, Crockett DP, Wong LY, Richardson JR, Sonsalla PK.

J Neurochem. 2008 Jul;106(1):231-43. doi: 10.1111/j.1471-4159.2008.05355.x. Epub 2008 Jul 1.

13.

Animal models of Parkinson's disease progression.

Meredith GE, Sonsalla PK, Chesselet MF.

Acta Neuropathol. 2008 Apr;115(4):385-98. doi: 10.1007/s00401-008-0350-x. Epub 2008 Feb 14. Review.

14.

Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.

Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendon├ža A.

Prog Neurobiol. 2007 Dec;83(5):310-31. Epub 2007 Sep 29. Review.

PMID:
18023959
15.

Mitochondrial stress-induced dopamine efflux and neuronal damage by malonate involves the dopamine transporter.

Moy LY, Wang SP, Sonsalla PK.

J Pharmacol Exp Ther. 2007 Feb;320(2):747-56. Epub 2006 Nov 7.

PMID:
17090704
16.
17.

Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).

Yazdani U, German DC, Liang CL, Manzino L, Sonsalla PK, Zeevalk GD.

Exp Neurol. 2006 Jul;200(1):172-83. Epub 2006 Mar 20.

PMID:
16546169
18.
19.
20.

8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.

Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli N Jr, Schwarzschild MA.

J Biol Chem. 2002 Sep 27;277(39):36040-4. Epub 2002 Jul 18.

21.

Protection of malonate-induced GABA but not dopamine loss by GABA transporter blockade in rat striatum.

Zeevalk GD, Manzino L, Sonsalla PK.

Exp Neurol. 2002 Jul;176(1):193-202.

PMID:
12093096
22.

Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment.

Gluck MR, Moy LY, Jayatilleke E, Hogan KA, Manzino L, Sonsalla PK.

J Neurochem. 2001 Oct;79(1):152-60.

23.

Differential sensitivity of mesencephalic neurons to inhibition of phosphatase 2A.

Zeevalk GD, Bernard LP, Manzino L, Sonsalla PK.

J Pharmacol Exp Ther. 2001 Sep;298(3):925-33.

PMID:
11504786
24.
25.

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA.

J Neurosci. 2001 May 15;21(10):RC143.

27.
28.
29.
30.
31.

NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.

Zeevalk GD, Manzino L, Sonsalla PK.

Exp Neurol. 2000 Feb;161(2):638-46.

PMID:
10686083
32.

Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism.

Sonsalla PK, Albers DS, Zeevalk GD.

Amino Acids. 1998;14(1-3):69-74. Review.

PMID:
9871444
33.
34.

The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.

Speciale SG, Liang CL, Sonsalla PK, Edwards RH, German DC.

Neuroscience. 1998 Jun;84(4):1177-85.

PMID:
9578404
35.

Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra.

Sonsalla PK, Manzino L, Sinton CM, Liang CL, German DC, Zeevalk GD.

Brain Res. 1997 Oct 31;773(1-2):223-6.

PMID:
9409726
36.

Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP.

Sanghera MK, Manaye K, McMahon A, Sonsalla PK, German DC.

Neuroreport. 1997 Oct 20;8(15):3327-31.

PMID:
9351666
37.
38.

Energy stress-induced dopamine loss in glutathione peroxidase-overexpressing transgenic mice and in glutathione-depleted mesencephalic cultures.

Zeevalk GD, Bernard LP, Albers DS, Mirochnitchenko O, Nicklas WJ, Sonsalla PK.

J Neurochem. 1997 Jan;68(1):426-9.

39.
40.

The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse.

German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, Sonsalla PK.

Neurodegeneration. 1996 Dec;5(4):299-312.

PMID:
9117541
41.

Treatment of mice with methamphetamine produces cell loss in the substantia nigra.

Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED.

Brain Res. 1996 Oct 28;738(1):172-5.

PMID:
8949944
43.
44.

The neurotoxin MPTP increases calbindin-D28k levels in mouse midbrain dopaminergic neurons.

Ng MC, Iacopino AM, Quintero EM, Marches F, Sonsalla PK, Liang CL, Speciale SG, German DC.

Brain Res Mol Brain Res. 1996 Mar;36(2):329-36.

PMID:
8965654
45.
46.
47.
49.

Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.

Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK.

J Pharmacol Exp Ther. 1994 Sep;270(3):1000-7.

PMID:
7932147
50.

Role of the 5-HT2 receptor in the methamphetamine-induced neurochemical alterations.

Johnson M, Sonsalla PK, Letter AA, Hanson GR, Gibb JW.

J Pharmacol Exp Ther. 1994 Jul;270(1):97-103.

PMID:
7913500

Supplemental Content

Loading ...
Support Center